Peritonitis pathophysiology

From El we 11 RJ, Foote EF. Hemodialysis and peritoneal dialysis. In DiPiro JT, Talbert RL, Yee GC, et al, (eds.) Pharmacotherapy A Pathophysiologic Approach. 6th ed. New York McGraw-Hill 2005 852, with permission. 

For more information on pruritus, see Chap. 48, Hemodialysis and Peritoneal Dialysis, authored by Edward F. Foote and Harold J. Manley, in Pharmacotherapy A Pathophysiologic Approach, seventh edition. 

Runyon B. Ascites and spontaneous bacterial peritonitis. In Eeldman M, Scharschmidt BE, Sleisenger MH, eds. Sleisenger and Eordtran s Gastrointestinal and Liver Disease Pathophysiology/Diagnosis/Treatment, 6th ed. Philadelphia, Saunders, 1998 1310-1333. 

Johnson CC, Baldessarre J, Levinson ME. Peritonitis Update on pathophysiology, chnical manifestations, and management. Chn Infect Dis 1997 24 1035-1047. 

Montravers P, Andremont A, Massias L, Carbon C. Investigation of the potential role of Streptococcus faecalis in the pathophysiology of experimental peritonitis. J Infect Dis 1994 169 821-830. 

Protectins (PDl) or Neuroprotectin Dl (NPDl) have been identified in the brain and other CNS model systans, and were first reported in 2003 (Hong et al. 2003). In other disease models not related to the brain, PDl has been found to have both antiinflammatory and protective properties in a wide range of pathophysiological models including ischemic stroke, obesity-insulin resistance and peritonitis amongst others... 

---